Last reviewed · How we verify
Artefenomel-Ferroquine
Artefenomel-Ferroquine is a Antimalarial Small molecule drug developed by Centre de Recherche Médicale de Lambaréné. It is currently in Phase 2 development for Treatment of uncomplicated Plasmodium falciparum malaria.
Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite.
Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite. Used for Treatment of uncomplicated Plasmodium falciparum malaria.
At a glance
| Generic name | Artefenomel-Ferroquine |
|---|---|
| Sponsor | Centre de Recherche Médicale de Lambaréné |
| Drug class | Antimalarial |
| Target | Plasmodium falciparum |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Artefenomel is a blood-stage antimalarial agent that inhibits the Plasmodium falciparum parasite's ability to infect red blood cells. Ferroquine is a liver-stage antimalarial agent that targets the parasite in the liver. The combination of artefenomel and ferroquine aims to provide a more effective treatment for malaria by targeting both the blood and liver stages of the parasite.
Approved indications
- Treatment of uncomplicated Plasmodium falciparum malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria (PHASE2)
- Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria (PHASE2)
- Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artefenomel-Ferroquine CI brief — competitive landscape report
- Artefenomel-Ferroquine updates RSS · CI watch RSS
- Centre de Recherche Médicale de Lambaréné portfolio CI
Frequently asked questions about Artefenomel-Ferroquine
What is Artefenomel-Ferroquine?
How does Artefenomel-Ferroquine work?
What is Artefenomel-Ferroquine used for?
Who makes Artefenomel-Ferroquine?
What drug class is Artefenomel-Ferroquine in?
What development phase is Artefenomel-Ferroquine in?
What are the side effects of Artefenomel-Ferroquine?
What does Artefenomel-Ferroquine target?
Related
- Drug class: All Antimalarial drugs
- Target: All drugs targeting Plasmodium falciparum
- Manufacturer: Centre de Recherche Médicale de Lambaréné — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of uncomplicated Plasmodium falciparum malaria
- Compare: Artefenomel-Ferroquine vs similar drugs
- Pricing: Artefenomel-Ferroquine cost, discount & access